Novo says CagriSema beat semaglutide on HbA1c and weight in REIMAGINE trials
The cagrilintide-semaglutide combination is Novo's bid to leapfrog its own best-seller in type 2 diabetes and obesity.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 16 03:00 ETSource: Pharmacy Times
The wire
- 01Pharmacy Times reports that across the REIMAGINE program, CagriSema produced greater HbA1c reductions and greater weight loss than semaglutide.
- 02The amylin-analog combination would give prescribers a higher-efficacy option from Novo as tirzepatide-class competition intensifies.
- 03Full endpoint figures, tolerability details and regulatory timing were not laid out in the summary, and comparative data come from the sponsor's own trials.
From the source
Read at pharmacytimes.comCagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials